These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23058309)

  • 1. Influence of cognitive function on speech and articulation rate in multiple sclerosis.
    Rodgers JD; Tjaden K; Feenaughty L; Weinstock-Guttman B; Benedict RH
    J Int Neuropsychol Soc; 2013 Feb; 19(2):173-80. PubMed ID: 23058309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Slowed articulation rate is associated with information processing speed decline in multiple sclerosis: A pilot study.
    Friedova L; Rusz J; Motyl J; Srpova B; Vodehnalova K; Andelova M; Novotna K; Novotny M; Ruzickova H; Tykalova T; Kubala Havrdova E; Horakova D; Uher T
    J Clin Neurosci; 2019 Jul; 65():28-33. PubMed ID: 31072740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Information-processing speed is the primary deficit underlying the poor performance of multiple sclerosis patients in the Paced Auditory Serial Addition Test (PASAT).
    Forn C; Belenguer A; Parcet-Ibars MA; Avila C
    J Clin Exp Neuropsychol; 2008 Oct; 30(7):789-96. PubMed ID: 18608672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unemployment in multiple sclerosis (MS): utility of the MS Functional Composite and cognitive testing.
    Strober L; Chiaravalloti N; Moore N; DeLuca J
    Mult Scler; 2014 Jan; 20(1):112-5. PubMed ID: 23635909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The symbol digit modalities test and the paced auditory serial addition test involve more than processing speed.
    Berrigan LI; LeFevre JA; Rees LM; Berard JA; Francis A; Freedman MS; Walker LAS
    Mult Scler Relat Disord; 2022 Dec; 68():104229. PubMed ID: 36279599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A one-year follow-up study of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) in relapsing-remitting multiple sclerosis: an appraisal of comparative longitudinal sensitivity.
    López-Góngora M; Querol L; Escartín A
    BMC Neurol; 2015 Mar; 15():40. PubMed ID: 25886168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery.
    Edgar C; Jongen PJ; Sanders E; Sindic C; Goffette S; Dupuis M; Jacquerye P; Guillaume D; Reznik R; Wesnes K
    BMC Neurol; 2011 Jun; 11():68. PubMed ID: 21649910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.
    Drake AS; Weinstock-Guttman B; Morrow SA; Hojnacki D; Munschauer FE; Benedict RH
    Mult Scler; 2010 Feb; 16(2):228-37. PubMed ID: 20028710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients.
    Niccolai C; Portaccio E; Goretti B; Hakiki B; Giannini M; Pastò L; Righini I; Falautano M; Minacapelli E; Martinelli V; Incerti C; Nocentini U; Fenu G; Cocco E; Marrosu MG; Garofalo E; Ambra FI; Maddestra M; Consalvo M; Viterbo RG; Trojano M; Losignore NA; Zimatore GB; Pietrolongo E; Lugaresi A; Pippolo L; Roscio M; Ghezzi A; Castellano D; Stecchi S; Amato MP
    BMC Neurol; 2015 Oct; 15():204. PubMed ID: 26472052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the French version of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS).
    Maubeuge N; Deloire MSA; Brochet B; Ehrlé N; Charré-Morin J; Saubusse A; Ruet A;
    Mult Scler Relat Disord; 2021 Feb; 48():102692. PubMed ID: 33352358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trail Making Test Could Predict Impairment in Cognitive Domains in Patients with Multiple Sclerosis: A Study of Diagnostic Accuracy.
    Kabiri S; Jameie M; Balali P; Adib Moradi S; Sanjari Moghaddam H; Aghamollaii V; Harirchian MH
    Arch Clin Neuropsychol; 2023 Jan; 38(1):37-48. PubMed ID: 35901460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Symbol Digit Modalities Test is an effective cognitive screen in pediatric onset multiple sclerosis (MS).
    Charvet LE; Beekman R; Amadiume N; Belman AL; Krupp LB
    J Neurol Sci; 2014 Jun; 341(1-2):79-84. PubMed ID: 24792098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive impairment of Japanese multiple sclerosis patients: Follow-up study using BRB-N assessment tool.
    Yoshii F; Takagi S; Nagata E; Hasegawa Y; Kunika N; Maki F; Mochizuki H; Ogino M; Kuroiwa Y
    J Neurol Sci; 2015 Dec; 359(1-2):323-7. PubMed ID: 26671136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive impairment and decline in different MS subtypes.
    Huijbregts SC; Kalkers NF; de Sonneville LM; de Groot V; Polman CH
    J Neurol Sci; 2006 Jun; 245(1-2):187-94. PubMed ID: 16643951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oralmotor slowing in multiple sclerosis: relationship to neuropsychological tasks requiring an oral response.
    Arnett PA; Smith MM; Barwick FH; Benedict RH; Ahlstrom BP
    J Int Neuropsychol Soc; 2008 May; 14(3):454-62. PubMed ID: 18419844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Callosal atrophy in multiple sclerosis is related to cognitive speed.
    Bergendal G; Martola J; Stawiarz L; Kristoffersen-Wiberg M; Fredrikson S; Almkvist O
    Acta Neurol Scand; 2013 Apr; 127(4):281-9. PubMed ID: 22988936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis.
    Batista S; Zivadinov R; Hoogs M; Bergsland N; Heininen-Brown M; Dwyer MG; Weinstock-Guttman B; Benedict RH
    J Neurol; 2012 Jan; 259(1):139-46. PubMed ID: 21720932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study.
    Morrow SA; Smerbeck A; Patrick K; Cookfair D; Weinstock-Guttman B; Benedict RH
    J Neurol; 2013 Feb; 260(2):489-97. PubMed ID: 23001556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Separate and Combined Influence of Cognitive Impairment and Dysarthria on Functional Communication in Multiple Sclerosis.
    Feenaughty L; Tjaden K; Weinstock-Guttman B; Benedict RHB
    Am J Speech Lang Pathol; 2018 Aug; 27(3):1051-1065. PubMed ID: 30054632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.
    Strober L; DeLuca J; Benedict RH; Jacobs A; Cohen JA; Chiaravalloti N; Hudson LD; Rudick RA; LaRocca NG;
    Mult Scler; 2019 Nov; 25(13):1781-1790. PubMed ID: 30334474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.